pLdCN Citations (3)
Originally described in: Optimized CRISPR-Cas9 Genome Editing for Leishmania and Its Use To Target a Multigene Family, Induce Chromosomal Translocation, and Study DNA Break Repair Mechanisms.Zhang WW, Lypaczewski P, Matlashewski G mSphere. 2017 Jan 18;2(1). pii: e00340-16. doi: 10.1128/mSphere.00340-16. eCollection 2017 Jan-Feb. PubMed Journal
Articles Citing pLdCN
| Articles |
|---|
Application of CRISPR/Cas9-Mediated Genome Editing in Leishmania.
Zhang WW, Lypaczewski P, Matlashewski G.
Methods Mol Biol. 2020;2116:199-224. doi: 10.1007/978-1-0716-0294-2_14.
PubMed
Associated Plasmids |
| LPG2 Gene Duplication in Leishmania infantum: A Case for CRISPR-Cas9 Gene Editing. Jesus-Santos FH, Lobo-Silva J, Ramos PIP, Descoteaux A, Lima JB, Borges VM, Farias LP. Front Cell Infect Microbiol. 2020 Aug 13;10:408. doi: 10.3389/fcimb.2020.00408. eCollection 2020. PubMed |
| The Phosphoenolpyruvate Carboxykinase Is a Key Metabolic Enzyme and Critical Virulence Factor of Leishmania major. Barazandeh AF, Mou Z, Ikeogu N, Mejia EM, Edechi CA, Zhang WW, Alizadeh J, Hatch GM, Ghavami S, Matlashewski G, Marshall AJ, Uzonna JE. J Immunol. 2021 Mar 1;206(5):1013-1026. doi: 10.4049/jimmunol.2000517. Epub 2021 Jan 18. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.